-+ 0.00%
-+ 0.00%
-+ 0.00%

VistaGen Therapeutics Reports Phase 3 Trial of Fasedienol for Social Anxiety Disorder Fails to Meet Primary Endpoint

Reuters·12/17/2025 13:30:47

Please log in to view news